Drugmaker Daiichi Sankyo reported to have received extended FDA approval for Azor, a combination pill containing amlodipine and olmesartan medoxomil, as an initial treatment for hypertensive patients who are expected to need multiple medications in order to reach their blood pressure targets. The original approval in September 2007 was for use alone or with other agents, but the indication for first-line therapy was recently added.